Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 + LVGN7409|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 10 VEGFR Inhibitor (Pan) 33||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|LVGN3616||LVGN-3616|LVGN 3616||Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 93||LVGN3616 is a humanized monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in restoration of T-cell mediated immune response (NCI Thesaurus).|
|LVGN6051||LVGN-6051|LVGN 6051||TNFRSF9 Antibody 17||LVGN6051 is a monoclonal antibody that targets 4-1BB (CD137) and acts as an agonist in the presence of Fc-gammaRIIB, potentially resulting in decreased tumor growth (PMID: 31105267).|
|LVGN7409||LVGN-7409|LVGN 7409||CD40 Antibody 13||LVGN7409 is an agonist antibody targeting CD40, which may lead to activation of downstream signaling and T-cell activity (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05075993||Phase I||Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 + LVGN7409 LVGN3616 + LVGN6051 + LVGN7409 + Nab-paclitaxel Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 LVGN3616 + LVGN6501 + Nab-paclitaxel||Study of LVGN3616 and LVGN6501±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors||Recruiting||USA||0|